This is what happens when societal guidance starts driving a new standard of care based on opinion rather than evidence. What has changed since 2024 that should lead clinicians around the world to start using cefiderocol instead of Bactrim, a drug we’ve used for decades with success? Has there been new clinical outcomes data or a meaningful change in in vitro susceptibility patterns worldwide? No. The answer seems to be simply: because IDSA 2026 AMR guidance said so.
Check out this study just published
Bactrim susceptibility 97.1% : Multinational surveillance program: US + Europe
@TSHP_org I tried to register online for the conference but online registration is closed although it is written until March 24 ..can you please reopen online registration..thank you
#BREAKING
UC Davis student, Karim Abou Najm, 20 was identified as the person who was stabbed at Sycamore Park on his way back from an undergraduate awards ceremony.
His father said, “We moved from Lebanon in 2018 hoping for safety”
Heartbreaking😢😓💔
#RestInPeaceKarimAbouNajm
Antimicrobial stewardship teams when asymptomatic bacteriuria is treated (outside of pregnancy and upcoming urological procedures).
#IDTwitter#stewardmeme#SymptomFreePeeLetItBe
#AAW non-clinical staff friendly cross word! Thank you @shaq_MD for the inspiration and @IDstewardship for the great drug name emoji game. 🍑 💊 We used this as a competition to kick off AAW today! #IDTwitter#WAAW2022@germerme
Cystatin C is a better marker of renal function than serum creatinine in early stages of AKI and is less affected by age, gender, muscle mass, and ethnicity.
Is concomitant use of vancomycin and beta-lactam associated with changes in Cystatin C? Great question, glad you asked!